Abstract：Objective To analyze the rationality of the use of oral antihypertensive drugs in 500 outpatients in a hospital from 2019 to 2020, so as to provide a reference for the safer and more effective use of antihypertensive drugs. Methods A total of 500 outpatient antihypertensive prescriptions were collected, and the rationality of drug variety selection, pharmacoeconomics, and drug combination was evaluated. Results CCB, ARB, and their compound preparations were mainly selected for drug varieties, among which amlodipine was used most frequently, and the varieties were consistent with WHO recommendations and related studies. The DUI of the top 10 drugs ranked by DDDs was between 0.9-1.0, and the dosage of drugs was basically reasonable and relatively stable. In the rationality review, 28 unreasonable prescriptions were found, accounting for 5.60% of the total prescription proportion, and the main unreasonable type was an unsuitable combination of medication, with a total of 12 cases accounting for 42.86%. The proportion of prescriptions for combined medication was relatively high (89.00%), and the combination drugs were mainly dual drugs, accounting for 64.27%, and CCB combined with ACEI/ARB was the mainstay, which was more reasonable. Conclusions The prescription of oral antihypertensive drugs in the outpatient department of our hospital is relatively standardized, but there are still unreasonable points, especially since the proportion of combination drugs is relatively high. The clinical use of antihypertensive drugs should follow the principle of individualization, and pharmacists need to strengthen prescription review and clinical education to further improve the level of rational drug use in hospitals.
刘新丰. 某医院2019—2020年门诊口服抗高血压用药500例处方合理性分析[J]. 中国校医, 2022, 36(12): 930-933,944.
LIU Xin-feng. Analysis of rationality of oral antihypertensive prescriptions for 500 outpatients in a hospital from 2019 to 2020. Chinese Journal of School Doctor, 2022, 36(12): 930-933,944.
[1] 《中国高血压防治指南》修订委员会.中国高血压防治指南2018年修订版[J].心脑血管病防治,2019,19(1):1-44. [2] 《中国心血管健康与疾病报告》编写组.《中国心血管健康与疾病报告2020》要点解读[J].中国心血管杂志,2021,26(3):209-218. [3] 陈炎,陈亚蓓,陶荣芳.医院处方点评管理规范(试行)[J].世界临床药物,2010,31(3):259-260. [4] 国家卫生计生委合理用药专家委员会,中国医师协会高血压中央委员会.高血压合理用药指南[J].中国医学前沿杂志(电子版),2015,7(6):22-64. [5] Teng L,Xin HW,Blix HS,et al. Review of the use of defined dailydose concept in drug utilisation research in China[J].Pharmacoep-idemiol Drug Saf,2012,21(10):1118-1124. [6] 王海峰,汪咏秋,卢苗青,等.帕金森病患者心脏自主神经功能的临床研究[J].现代实用医学,2013,25(4):396. [7] 崔宇超,李雄方.基层社区利用健康档案对辖区内高血压患者用药情况的统计与点评[J].今日药学,2015,25(4):303-305. [8] 杨啊晶.北京大学医院抗高血压药物应用分析[J].中国校医,2010,24(10):785-787. [9] 赵蔚. 2014—2016年北京市20所高校社区医院口服抗高血压药物使用情况分析[J].中国校医,2020,34(1):38-40,48. [10] 史倞,刘博巽,孔祥清.从《国际高血压学会2020国际高血压实践指南》再看单片复方制剂[J].中华高血压杂志,2020,28(10):912-914. [11] 陈修,陈维洲,曾贵云.心血管药理学[M].3版.北京:人民卫生出版社,2002:350. [12] 杜广清,马辉,王汝龙.以平均治疗日数开展药物利用动态监测的原理及注意事项[J].中国医药,2009,4(3):232-233. [13] 张婉馨.我院门诊抗高血压药的应用情况分析[J].海峡药学,2018,30(4):243-245. [14] 李清,苏畅,潘丽.某院门诊口服抗高血压国家基本药物应用分析[J].实用医技杂志,2019,26(10):1288-1290. [15] Zheng B,Li N,Hu Z,et al. From population to individuals:A newindicator for evaluating the appropriateness of clinical applicationof antibiotics[J]. BMC Pharmacol Toxicol,2018,19(1):55. [16] 闫鹏丽.不同级别医院门诊抗高血压药物调查分析[D].天津:天津医科大学,2014:1-59.
2022, Vol. 36 
